H. Lundbeck A/S

Copenhagen Stock Exchange:HLUN-B.CO

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

Denmark

Market Cap

USD 5.39 B

Share Price

USD 5.57

Avg Daily Volume

582,647

Change (1 day)

-1.21%

Change (1 year)

0.93%

Change (YTD)

-3.01%

H. Lundbeck A/S Operating Cash Flow for the year ending December 31, 2024: USD 460.32 M

H. Lundbeck A/S Operating Cash Flow is USD 460.32 M for the year ending December 31, 2024, a -23.78% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

H. Lundbeck A/S Operating Cash Flow for the year ending December 31, 2023 was USD 603.92 M, a 19.59% change year over year.
H. Lundbeck A/S Operating Cash Flow for the year ending December 31, 2022 was USD 504.98 M, a 45.42% change year over year.
H. Lundbeck A/S Operating Cash Flow for the year ending December 31, 2021 was USD 347.25 M, a -44.75% change year over year.
H. Lundbeck A/S Operating Cash Flow for the year ending December 31, 2020 was USD 628.50 M, a 60.92% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

Copenhagen Stock Exchange: HLUN-B.CO

H. Lundbeck A/S

CEO	Mr. Charl van Zyl
IPO Date	June 10, 2022
Location	Denmark
Headquarters	Ottiliavej 9
Employees	5,707
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.